Unique treatment could overcome treatment resistance and transform the fight against cancer
Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches
02-Feb-2023 -
Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, announced the closing of an oversubscribed $49million SeriesB financing. The financing was co-led by Pfizer Ventures and Earlybird ...
antigens
cancer
neoantigens
+2